Aurobindo Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Aurobindo Pharma has a total shareholder equity of ₹298.5B and total debt of ₹66.5B, which brings its debt-to-equity ratio to 22.3%. Its total assets and total liabilities are ₹450.7B and ₹152.2B respectively. Aurobindo Pharma's EBIT is ₹47.8B making its interest coverage ratio 139.5. It has cash and short-term investments of ₹63.3B.
Key information
22.3%
Debt to equity ratio
₹66.48b
Debt
| Interest coverage ratio | 139.5x |
| Cash | ₹63.26b |
| Equity | ₹298.51b |
| Total liabilities | ₹152.21b |
| Total assets | ₹450.72b |
Recent financial health updates
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Recent updates
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Apr 14Financial Position Analysis
Short Term Liabilities: AUROPHARMA's short term assets (₹242.1B) exceed its short term liabilities (₹122.0B).
Long Term Liabilities: AUROPHARMA's short term assets (₹242.1B) exceed its long term liabilities (₹30.2B).
Debt to Equity History and Analysis
Debt Level: AUROPHARMA's net debt to equity ratio (1.1%) is considered satisfactory.
Reducing Debt: AUROPHARMA's debt to equity ratio has reduced from 50.1% to 22.3% over the past 5 years.
Debt Coverage: AUROPHARMA's debt is well covered by operating cash flow (36.6%).
Interest Coverage: AUROPHARMA's interest payments on its debt are well covered by EBIT (139.5x coverage).